Comparison of a direct vs consultative advanced heart failure role in the outcomes of extracorporeal membrane oxygenation patients

Table 2 Comparison of survival outcomes in a cohort of extracorporeal membrane oxygenation patients with direct vs consultative advanced heart failure and transplant involvement

	Total (n = 51)	With direct AHFTC role (n = 21)	With consultative AHFTC role (n = 30)	Unadjusted odds ratio	P value	Adjusted odds ratio1	P value
Total survival after decannulation (%)	32/51 (63)	15/21 (71)	17/30 (57)	1.6 (0.5-5.6)	0.46	1.6 (0.4-5.6)	0.49
Total survival to 30 days post discharge (%)	23/51 (45)	14/21 (67)	9/30 (30)	4.7 (1.4-15)	0.01	5.3 (1.5-19)	0.01
VA survival after decannulation (%)	17/26 (65)	8/11 (73)	9/15 (60)	2.25 (0.4-14.6)	0.40	2.20 (0.3-16)	0.43
VA survival to 30 days post discharge (%)	10/26 (38)	7/11 (64)	3/15 (20)	7.0 (1.2-40.8)	0.03	6.4 (1.0-41.7)	0.05
VV survival after decannulation. (%)	15/25 (60)	7/10 (70)	8/15 (53)	1.7 (0.6-5.9)	0.43	1.8 (0.7-6.1)	0.45
VV survival to 30 days post discharge (%)	13/25 (52)	7/10 (70)	6/15 (40)	3.5 (0.6-19.2)	0.15	4.8 (0.71-32.2)	0.11

¹Adjusted for age and gender.

AHFTC: Advanced heart failure and transplant; VV: Veno-venous; VA: Veno-arterial.